| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PAI2 |
| Uniprot No | P05120 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-415aa |
| 氨基酸序列 | MEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQFNEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGNYLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGKIPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREKLNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKMAEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMVDVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP |
| 预测分子量 | 50.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条与PAI-2(纤溶酶原激活物抑制剂2)重组蛋白相关的虚拟参考文献示例(内容为模拟概括，非真实文献)：
---
1. **文献名称**: "Expression and functional characterization of recombinant human plasminogen activator inhibitor-2 in Escherichia coli"
**作者**: Smith J, et al.
**摘要**: 研究报道了利用大肠杆菌表达系统成功制备重组人PAI-2蛋白，并通过体外实验验证其抑制尿激酶型纤溶酶原激活物(uPA)的活性，为PAI-2的机制研究提供工具。
2. **文献名称**: "PAI-2 modulates tumor cell apoptosis via interaction with proteasome components"
**作者**: Lee H, et al.
**摘要**: 通过哺乳动物细胞表达重组PAI-2.发现其通过结合蛋白酶体亚基抑制肿瘤细胞凋亡，提示PAI-2在癌症进展中的潜在调控作用。
3. **文献名称**: "Structural analysis of recombinant PAI-2 reveals its conformational stability under oxidative stress"
**作者**: Wang Y, et al.
**摘要**: 利用真核表达系统获得高纯度PAI-2重组蛋白，通过X射线晶体学解析其三维结构，发现其独特的抗氧化物诱导变性的特性，可能与细胞内应激保护功能相关。
---
注：以上文献信息为模拟概括，实际研究中建议通过PubMed或Web of Science检索真实文献。
**Background of PAI-2 Recombinant Protein**
Plasminogen Activator Inhibitor 2 (PAI-2), also known as SerpinB2. is a member of the serine protease inhibitor (serpin) superfamily. It primarily inhibits urokinase-type plasminogen activator (uPA), a key enzyme involved in extracellular matrix (ECM) degradation, cell migration, and tissue remodeling. PAI-2 exists in both intracellular and secreted forms, with its expression being strongly induced by inflammatory cytokines, hormones, and cellular stress, particularly in monocytes, macrophages, and placental tissues.
Structurally, PAI-2 is a single-chain glycoprotein containing two domains: a reactive center loop (RCL) responsible for protease binding and a stable serpin core. Unlike PAI-1. its closely related homolog, PAI-2 exhibits unique stability under physiological conditions and plays dual roles in fibrinolysis regulation and intracellular signaling. Its intracellular form is implicated in inhibiting apoptosis, potentially through interactions with caspases or other apoptotic pathways.
Recombinant PAI-2 is produced using expression systems like *E. coli* or mammalian cells, enabling large-scale purification for research and therapeutic applications. Studies highlight its relevance in cancer biology, as uPA-mediated ECM breakdown facilitates tumor invasion and metastasis. PAI-2’s ability to inhibit uPA positions it as a potential therapeutic agent to curb cancer progression. Additionally, PAI-2 is linked to pregnancy maintenance, immune modulation, and inflammatory diseases, where its anti-apoptotic and anti-inflammatory properties may offer clinical benefits.
Despite its promise, challenges remain in optimizing recombinant PAI-2 production to ensure proper folding and post-translational modifications. Ongoing research explores its dual roles in different pathological contexts, aiming to harness its therapeutic potential while deciphering its complex biological mechanisms.
×
